Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2021-05-17 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-05-17 English
Other.pdf
Regulatory Filings
2021-05-13 English
Underwriting or agency agreements (or amendment thereto).pdf
Governance Information Classification · 100% confidence The document is titled 'AMENDED AND RESTATED INCENTIVE STOCK OPTION PLAN' for Perk Labs Inc. It contains detailed definitions, purpose, administration, and terms related to the company's stock option plan. This is a governance-related document outlining internal rules and policies regarding stock options for directors, officers, employees, and consultants. It does not contain financial statements, earnings data, voting results, or regulatory announcements. It is not a report or announcement of a report but a formal governance document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full plan document, not a brief announcement or certification.
2021-05-13 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter of consent from a legal firm regarding a Prospectus Supplement related to an offering of Units by Tetra Bio-Pharma Inc. It references the Prospectus Supplement and legal opinions but does not contain financial data, management discussion, or report content. The document is short (1777 characters) and serves as a regulatory communication rather than a financial report or announcement of voting results, management changes, or earnings. It is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2021-05-13 English
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement related to a securities offering by Tetra Bio-Pharma Inc. It discusses the issuance of units consisting of common shares and warrants, underwriting agreements, pricing, over-allotment options, and regulatory compliance with securities laws. The content focuses on fundraising and capital raising activities, including underwriting fees and terms of the offering. There is no financial performance data, earnings information, or management discussion of results. The document is clearly an update on a capital raising transaction, qualifying the distribution of securities and related warrants. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to explicit references to underwriting, offering price, and securities distribution terms.
2021-05-13 English
Underwriting or agency agreements (or amendment thereto).pdf
Regulatory Filings
2021-05-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.